316 related articles for article (PubMed ID: 30851646)
21. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.
Hugle M; Belz K; Fulda S
Cell Death Differ; 2015 Dec; 22(12):1946-56. PubMed ID: 26024389
[TBL] [Abstract][Full Text] [Related]
22. Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.
Lub S; Maes A; Maes K; De Veirman K; De Bruyne E; Menu E; Fostier K; Kassambara A; Moreaux J; Hose D; Leleu X; King RW; Vanderkerken K; Van Valckenborgh E
Oncotarget; 2016 Jan; 7(4):4062-76. PubMed ID: 26716651
[TBL] [Abstract][Full Text] [Related]
23. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.
Jiang L; Siu MK; Wong OG; Tam KF; Lu X; Lam EW; Ngan HY; Le XF; Wong ES; Monteiro LJ; Chan HY; Cheung AN
Clin Cancer Res; 2011 Nov; 17(21):6924-33. PubMed ID: 21926165
[TBL] [Abstract][Full Text] [Related]
24. DITMD-induced mitotic defects and apoptosis in tumor cells by blocking the polo-box domain-dependent functions of polo-like kinase 1.
Kim KU; Lee JH; Lee MY; Chae CH; Lee JH; Lee BH; Oh KS
Eur J Pharmacol; 2019 Mar; 847():113-122. PubMed ID: 30689997
[TBL] [Abstract][Full Text] [Related]
25. Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells.
Schmidt M; Hofmann HP; Sanders K; Sczakiel G; Beckers TL; Gekeler V
Mol Cancer Ther; 2006 Apr; 5(4):809-17. PubMed ID: 16648550
[TBL] [Abstract][Full Text] [Related]
26. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
[TBL] [Abstract][Full Text] [Related]
27. Bcl-2 degradation is an additional pro-apoptotic effect of polo-like kinase inhibition in cholangiocarcinoma cells.
Sydor S; Jafoui S; Wingerter L; Swoboda S; Mertens JC; Gerken G; Canbay A; Paul A; Fingas CD
World J Gastroenterol; 2017 Jun; 23(22):4007-4015. PubMed ID: 28652654
[TBL] [Abstract][Full Text] [Related]
28. PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells.
Raab M; Sanhaji M; Matthess Y; Hörlin A; Lorenz I; Dötsch C; Habbe N; Waidmann O; Kurunci-Csacsko E; Firestein R; Becker S; Strebhardt K
Nat Commun; 2018 Mar; 9(1):1106. PubMed ID: 29549256
[TBL] [Abstract][Full Text] [Related]
29. miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin.
Guo P; Xiong X; Zhang S; Peng D
Oncol Rep; 2016 Dec; 36(6):3552-3558. PubMed ID: 27748936
[TBL] [Abstract][Full Text] [Related]
30. Tumor suppressor BLU promotes paclitaxel antitumor activity by inducing apoptosis through the down-regulation of Bcl-2 expression in tumorigenesis.
Park ST; Byun HJ; Kim BR; Dong SM; Park SH; Jang PR; Rho SB
Biochem Biophys Res Commun; 2013 May; 435(1):153-9. PubMed ID: 23628417
[TBL] [Abstract][Full Text] [Related]
31. Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells.
Lindon C; Pines J
J Cell Biol; 2004 Jan; 164(2):233-41. PubMed ID: 14734534
[TBL] [Abstract][Full Text] [Related]
32. The evi5 oncogene regulates cyclin accumulation by stabilizing the anaphase-promoting complex inhibitor emi1.
Eldridge AG; Loktev AV; Hansen DV; Verschuren EW; Reimann JD; Jackson PK
Cell; 2006 Jan; 124(2):367-80. PubMed ID: 16439210
[TBL] [Abstract][Full Text] [Related]
33. Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1.
Hansen DV; Loktev AV; Ban KH; Jackson PK
Mol Biol Cell; 2004 Dec; 15(12):5623-34. PubMed ID: 15469984
[TBL] [Abstract][Full Text] [Related]
34. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
35. TPX2 promotes cell proliferation and migration via PLK1 in OC.
Ma S; Rong X; Gao F; Yang Y; Wei L
Cancer Biomark; 2018; 22(3):443-451. PubMed ID: 29865033
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxic mechanism of PLK1 inhibitor GSK461364 against osteosarcoma: Mitotic arrest, apoptosis, cellular senescence, and synergistic effect with paclitaxel.
Chou YS; Yen CC; Chen WM; Lin YC; Wen YS; Ke WT; Wang JY; Liu CY; Yang MH; Chen TH; Liu CL
Int J Oncol; 2016 Mar; 48(3):1187-94. PubMed ID: 26794530
[TBL] [Abstract][Full Text] [Related]
37. Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome.
Moshe Y; Boulaire J; Pagano M; Hershko A
Proc Natl Acad Sci U S A; 2004 May; 101(21):7937-42. PubMed ID: 15148369
[TBL] [Abstract][Full Text] [Related]
38. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.
Zhang Y; Sriraman SK; Kenny HA; Luther E; Torchilin V; Lengyel E
Mol Cancer Ther; 2016 Oct; 15(10):2282-2293. PubMed ID: 27466355
[TBL] [Abstract][Full Text] [Related]
39. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
40. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
